New open source drug discovery project aims to develop mycetoma treatment

Geneva, Rotterdam, Sydney – 6 February 2018
The MycetOS (Mycetoma Open Source) project was launched today by the University of Sydney, Erasmus MC, and DNDi to use an Open Pharma approach to discover compounds that could lead to new treatments for patients suffering from fungal mycetoma (eumycetoma), a devastating disease for which current treatments are ineffective, expensive, and toxic.

ISGlobal XIV Taller sobre la enfermedad de Chagas

8 March 2018
Barcelona, Spain
Sergio Sosa-Estani, Head of Chagas, DNDi Latin America – presentation about control programmes for congenital Chagas disease
Michel Lotrowska, Acting Regional Director, DNDi Latin America – participation in the annual meeting Chagas coalition

Sanofi et la DNDi soumettent leur traitement contre la maladie du sommeil à l’évaluation de l’Agence européenne des médicaments ​

Paris, Genève – 31 janvier 2018
Sanofi a soumis le dossier du féxinidazole dans le traitement de la maladie du sommeil à l’évaluation de l’Agence européenne des médicaments (EMA). Le féxinidazole est développé en collaboration avec la Drugs for Neglected Disease initiative (DNDi, initiative Médicaments contre les maladies négligées). Il serait le premier traitement entièrement par voie orale actuellement développé dans le traitement de la forme de trypanosomiase humaine africaine (ou maladie du sommeil) causée par le parasite Trypanosoma brucei gambiense (g-HAT). Ce médicament pourrait contribuer à l’éradication de la maladie.

Sanofi, DNDi seek European Medicines Agency review for sleeping sickness treatment

Paris, Geneva – 31 January 2018
Sanofi has asked the European Medicines Agency (EMA) to review fexinidazole for the treatment of sleeping sickness. Fexinidazole is being developed in collaboration with the Drugs for Neglected Disease initiative (DNDi). It would be the first all-oral treatment under investigation for Trypanosoma brucei gambiense human African trypanosomiasis (g-HAT), commonly known as sleeping sickness. This treatment is expected to contribute to the elimination of the disease.